Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4460257
Max Phase: Preclinical
Molecular Formula: C11H13F2NO
Molecular Weight: 213.23
Molecule Type: Unknown
Associated Items:
ID: ALA4460257
Max Phase: Preclinical
Molecular Formula: C11H13F2NO
Molecular Weight: 213.23
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)(C)/[N+]([O-])=C/c1ccc(F)c(F)c1
Standard InChI: InChI=1S/C11H13F2NO/c1-11(2,3)14(15)7-8-4-5-9(12)10(13)6-8/h4-7H,1-3H3/b14-7-
Standard InChI Key: UDGLEOVYEDTMAT-AUWJEWJLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 213.23 | Molecular Weight (Monoisotopic): 213.0965 | AlogP: 2.69 | #Rotatable Bonds: 1 |
Polar Surface Area: 26.07 | Molecular Species: ACID | HBA: 1 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 2 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 0.68 | CX Basic pKa: | CX LogP: -0.16 | CX LogD: 1.87 |
Aromatic Rings: 1 | Heavy Atoms: 15 | QED Weighted: 0.30 | Np Likeness Score: -1.05 |
1. (2013) Compositions and methods of inhibiting retinal degeneration, |
Source(1):